1-(4-chlorophenyl)-2-phenyl-2-propylamine | 129060-79-3

• 英文名称: 1-(4-chlorophenyl)-2-phenyl-2-propylamine
• 英文别名: 1-(4-Chlorophenyl)-2-phenylpropan-2-amine
• CAS: 129060-79-3
• 化学式: C₁₅H₁₆ClN
• 分子量: 245.752
• InChiKey: SZNKIJVBDJSGHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
  申请人：Astra Aktiebolag

  公开号：EP0356035A2

  公开（公告）日：1990-02-28

  There is provided the use of a compound of formula I in the preparation of a medicament for use in the prevention or treatment of neurological disorders, wherein, Ar₁ and Ar₂, which may be the same or different, independently represent phenyl substituted by one or more of amino, nitro chlorine, bromine, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano; in addition one of Ar₁ or Ar₂ may also represent phenyl; R₁ represents hydrogen or C1 to 6 alkyl; R₂ represents hydrogen or COCH₂NH₂; R₃ represents hydrogen or C1 to 6 alkyl; provided that when R₂ represents hydrogen, then one or both of Ar₁ and Ar₂ may also represent phenyl, fluorophenyl or 2-, 3- or 4- pyridinyl and R₁ may also represent C1 to 6 alkoxycarbonyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof. Some of the compounds of formula I are novel, and there are provided processes for making these, together with processes for making pharmaceutical compositions containing the novel compounds.

  提供了式 I 化合物在制备用于预防或治疗神经系统疾病的药物中的用途、 其中 Ar₁和Ar₂可以相同或不同，独立地代表被氨基、硝基氯、溴、羟基、C1～6 烷氧基、C1～6 烷基或氰基中的一个或多个取代的苯基；此外，Ar₁或Ar₂中的一个也可以代表苯基； R₁ 代表氢或 C1 至 6 烷基； R₂ 代表氢或 COCH₂NH₂； R₃ 代表氢或 C1 至 6 烷基； 但当 R₂ 代表氢时，Ar₁ 和 Ar₂ 中的一个或两个也可代表苯基、氟苯基或 2-、3- 或 4-吡啶基，R₁ 也可代表 C1-6 烷氧羰基或三氟甲基； 或其药学上可接受的盐。 式 I 的某些化合物是新型的，提供了制造这些化合物的工艺以及制造含有新型化合物的药物组合物的工艺。
• Arylalkylamides having neuroprotective properties
  申请人：FISONS CORPORATION

  公开号：EP0648489A1

  公开（公告）日：1995-04-19

  The use of 2-amino-N-(1,2-diphenyl-1-methylethyl)acetamide, 2-amino-N-(1,2-diphenylethyl)acetamide and 2-amino-N-[1,2-bis(4-fluorophenyl)-1-methylethyl]acetamide, and pharmaceutically acceptable salts thereof, as active ingredients in the manufacture of neuroprotective medicaments, is provided.

  提供了 2-氨基-N-(1,2-二苯基-1-甲基乙基)乙酰胺、2-氨基-N-(1,2-二苯基乙基)乙酰胺和 2-氨基-N-[1,2-双(4-氟苯基)-1-甲基乙基]乙酰胺及其药学上可接受的盐作为活性成分用于制造神经保护药物。
• Arylalkylamine having anticonvulsant and neuroprotective properties
  申请人：Astra Aktiebolag

  公开号：EP0648745A1

  公开（公告）日：1995-04-19

  The invention provides (S)-1-phenyl-2-(2-pyridinyl)ethylamine, and its pharmaceutically acceptable salts. The compound is indicated as an anticonvulsant and neuroprotective agent.

  本发明提供了(S)-1-苯基-2-(2-吡啶基)乙胺及其药学上可接受的盐类。该化合物可用作抗惊厥剂和神经保护剂。
• COMPOSITIONS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS
  申请人：Case Western Reserve University

  公开号：EP3485882A1

  公开（公告）日：2019-05-22

  A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).

  一种治疗受试者广泛性发育障碍的方法，包括向受试者施用一定量的NMDAR拮抗剂，以有效改善受试者与编码甲基-CPG结合蛋白2（MeCP2）基因的功能缺失突变相关的生化和功能异常。
• NMDAR antagonist for the treatment of pervasive development disorders
  申请人：Case Western Reserve University

  公开号：US10555916B2

  公开（公告）日：2020-02-11

  A method of treating a pervasive development disorder in a subject includes administering to the subject an amount of an NMDAR antagonist effective to ameliorate biochemical and functional abnormalities in the subject associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein 2 (MeCP2).

  一种治疗受试者广泛性发育障碍的方法，包括向受试者施用一定量的NMDAR拮抗剂，以有效改善受试者与编码甲基-CPG结合蛋白2（MeCP2）基因的功能缺失突变相关的生化和功能异常。